In vivo efficacy of HD0471953: A novel GPR119 agonist for the treatment of type 2 diabetes mellitus

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Kim, So Ra ^a   Kim, Dae Hoon ^a,b   Park, Soo Hyun ^b   Kim, Young Seok ^a   Kim, Chun Hwa ^a   Ha, Tae Young ^a   Yang, Jin ^a   Rhee, Jae Keol ^a  

^a Hyundai Pharmaceutical Co Ltd   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GPR119 PROTEIN, MOUSE;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; MALE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, G-PROTEIN-COUPLED; TREATMENT OUTCOME;

EID: 84893811054     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/269569     Document Type: Article

References (22)

1. DeFronzo R. A., Bonadonna R. C., Ferrannini E., Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992 15 3 318 368 2-s2.0-0026590484
2. Taylor S. I., Accili D., Imai Y., Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes 1994 43 6 735 740 2-s2.0-0028229508
3. Meece J., Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Current Medical Research and Opinion 2007 23 4 933 944 2-s2.0-34247362354 10.1185/030079906X167336 (Pubitemid 46631496)
4. Ho J., Leung A. K. C., Rabi D., Hypoglycemic agents in the management of type 2 diabetes mellitus. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery 2011 5 1 66 73 2-s2.0-79551632306 10.2174/187221411794351879
5. Ross S. A., Ekoé J.-M., Incretin agents in type 2 diabetes. Canadian Family Physician 2010 56 7 639 648 2-s2.0-77956581914
6. Chu Z.-L., Jones R. M., He H., Carroll C., Gutierrez V., Lucman A., Moloney M., Gao H., Mondala H., Bagnol D., Unett D., Liang Y., Demarest K., Semple G., Behan D. P., Leonard J., A role for β -cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007 148 6 2601 2609 2-s2.0-34248527678 10.1210/en.2006-1608 (Pubitemid 46984798)
7. Jones R. M., Leonard J. N., Buzard D. J., Lehmann J., GPR119 agonists for the treatment of type 2 diabetes. Expert Opinion on Therapeutic Patents 2009 19 10 1339 1359 2-s2.0-70349770172 10.1517/13543770903153878
8. Barnett A., DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International Journal of Clinical Practice 2006 60 11 1454 1470 2-s2.0-33749834648 10.1111/j.1742-1241.2006.01178.x (Pubitemid 44560347)
9. Overton H. A., Fyfe M. C. T., Reynet C., GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. British Journal of Pharmacology 2008 153 supplement 1 S76 S81 2-s2.0-40349114501 10.1038/sj.bjp.0707529 (Pubitemid 351340991)
10. Burge M. R., Sood V., Sobhy T. A., Rassam A. G., Schade D. S., Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. Diabetes, Obesity and Metabolism 1999 1 4 199 206 2-s2.0-0033157113
11. Amiel S. A., Dixon T., Mann R., Jameson K., Hypoglycaemia in type 2 diabetes. Diabetic Medicine 2008 25 3 245 254 2-s2.0-40049106685 10.1111/j.1464-5491.2007.02341.x (Pubitemid 351322690)
12. Tang W. H. W., Do thiazolidinediones cause heart failure? A critical review. Cleveland Clinic Journal of Medicine 2006 73 4 390 397 2-s2.0-33646077426 10.3949/ccjm.73.4.390
13. Creutzfeldt W., Ebert R., New developments in the incretin concept. Diabetologia 1985 28 8 565 573 2-s2.0-0021864130 (Pubitemid 15017390)
14. Iltz J. L., Baker D. E., Setter S. M., Keith Campbell R., Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clinical Therapeutics 2006 28 5 652 665 2-s2.0-33745970187 10.1016/j.clinthera.2006.05. 006 (Pubitemid 44067260)
15. Barnett A., Allsworth J., Jameson K., Mann R., A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Current Medical Research and Opinion 2007 23 7 1493 1507 2-s2.0-34547161425 10.1185/030079907X199691 (Pubitemid 47122158)
16. Raun K., von Voss P., Gotfredsen C. F., Golozoubova V., Rolin B., Knudsen L. B., Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007 56 1 8 15 2-s2.0-33847072735 10.2337/db06-0565
17. Bekur R., Nagaraja M. V., Shivashankara K. N., Stanley W., Sitagliptin-induced hemolysis. Indian Journal of Pharmacology 2010 42 5 320 321 2-s2.0-77957728007 10.4103/0253-7613.70405
18. Iyer S. N., Drake A. J. III, West R. L., Mendez C. E., Tanenberg R. J., Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocrine Practice 2012 18 1 e10 e13 2-s2.0-84857573175 10.4158/EP11264.CR
19. Yokota K., Igaki N., Sitagliptin (dpp-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Journal of Internal Medicine 2012 51 15 2041 2044
20. Drucker D. J., Jin T., Asa S. L., Young T. A., Brubaker P. L., Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Molecular Endocrinology 1994 8 12 1646 1655 2-s2.0-0028575660
21. Chu Z.-L., Jones R. M., He H., Carroll C., Gutierrez V., Lucman A., Moloney M., Gao H., Mondala H., Bagnol D., Unett D., Liang Y., Demarest K., Semple G., Behan D. P., Leonard J., A role for β -cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007 148 6 2601 2609 2-s2.0-34248527678 10.1210/en.2006-1608 (Pubitemid 46984798)
22. Giorgino F., Leonardini A., Natalicchio A., Laviola L., Multifactorial intervention in type 2 diabetes: the promise of incretin-based therapies. Journal of Endocrinological Investigation 2011 34 1 69 77 2-s2.0-79955397107 10.3275/7444